Because CRF is a critical linking factor of LC-NE and HPA axis function, these data suggest that pharmacological targeting of CRF-R1 and other CRF-related targets may have therapeutic potential as an early stage intervention to halt the progression of AD pathology (Vandael and Gounko, 2019). Here, CRH is linked to Alzheimer disease.